A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 2, 1999, Pages 127-147

  Meibohm, Bernd ^a,c   Hochhaus, Günther ^a   Möllmann, Helmut ^b   Barth, Jürgen ^b   Wagner, Melanie ^b   Krieg, Michael ^b   Stöckmann, Ricarda ^b   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Corticosteroids; Cortisol suppression; Inhalation; PK PD modeling; Surrogate marker

Indexed keywords

CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; METHYLPREDNISOLONE; TRIAMCINOLONE ACETONIDE;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; CALCULATION; CIRCADIAN RHYTHM; CORTICOSTEROID THERAPY; DISEASE MARKER; DOSE RESPONSE; DRUG SPECIFICITY; HUMAN; HYDROCORTISONE RELEASE; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ALGORITHMS; AREA UNDER CURVE; DEPRESSION, CHEMICAL; HUMANS; HYDROCORTISONE; MODELS, BIOLOGICAL;

EID: 0032822407     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020670421957     Document Type: Article

References (55)

1. P. J. Barnes and S. Pedersen. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148:s1-s26 (1993).
2. S. E. Overbeek, H. A. Kerstjens, J. M. Bogaard, P. G. Mulder, and D. S. Postma. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? Chest 110:35-41 (1996).
3. R. Brattsand, A. Thalen, K. Roempke, L. Källström, and E. Gruvstad. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur. J. Resp. Dis. 122:62-73 (1982).
4. S. J. Szefler. Glucocorticoid therapy for asthma: Clinical pharmacology. J. Allergy Clin. Immunol. 88:147-162 (1991).
5. P. J. Barnes. Inhaled glucocorticoids for asthma. New Engl. J. Med. 332:868-875 (1995).
6. C. Falcoz, A. E. Mackie, J. McDowall, J. McRae, L. Yogendran, G. P. Ventresca, and A. Bye. Oral bioavailability of fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 41:459P-460P (1996).
7. H. Derendorf, G. Hochhaus, S. Rohatagi, H. Möellmann, J. Barth, H. Sourgens, and M. Erdmann. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J. Clin. Pharmacol. 35:302-305 (1995).
8. J. W. Honour. Hypothalamic-pituitary-adrenal axis. Resp. Med. 88:9-15 (1994).
9. E. D. Weitzman, D. Fukushima, C. Nogeire, H. Roffwarg, T. F. Gallagher, and L. Hellman. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J. Clin. Endocrinol. Metab. 33:14-22 (1970).
10. B. Sherman, C. Wysham, and B. Pfohl. Age-related changes in the circadian rhythm of plasma cortisol in man. J. Clin. Endocrinol. Metab. 61:439-443 (1985).
11. A.-N. Kong, E. A. Ludwig, R. L. Slaughter, P. M. DiStefano, J. DeMasi, E. Middleton, and W. J. Jusko. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin. Pharmacol Ther. 46:616-627 (1989).
12. J. A. Wald, R. M. Law, E. A. Ludwig, R. R. Sloan, E. Middleton, and W. J. Jusko. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J. Pharmacokin. Biopharm. 20:567-589 (1992).
13. R. P. Koopmans, M. C. P. Braat, B. Oosterhuis, and C. J. VanBoxtel. Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. J. Pharmacol. Exp. Ther. 262:503-508 (1992).
14. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, E. Galia, M. Erdmann, H. Sourgens, and H. Derendorf. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral and inhaled administration. J. Clin. Pharmacol. 35:1187-1193(1995).
15. S. Rohatagi, A. Bye, C. Falcoz, A. E. Mackie, B. Meibohm, H. Möllmann, and H. Derendorf. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J. Clin. Pharmacol. 36:938-941 (1996).
16. S. Rohatagi, U. Täuber, K. Richter, and H. Derendorf. Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J. Clin. Pharmacol. 36:311-314 (1996).
17. S. Rohatagi, A. Bye, A. E. Mackie, and H. Derendorf. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur. J. Pharm. Sci. 4:341-350 (1996).
18. J. D. Veldhuis, A. Iranmanesh, G. Lizarralde, and M. L. Johnson. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am. J. Physiol. 257:E6-14 (1989).
19. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf, M. Krieg, H. Weisser, and A. Möllmann. Pharmacokinetics and pharmacodynamics of cloprednol. Int. J. Clin. Pharmacol Ther. 34:1-5 (1996).
20. B. Meibohm, G. Hochhaus, S. Rohatagi, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann, and H. Derendorf. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J. Clin. Pharmacol 37:704-710 (1997).
21. M. Phillip, M. Aviram, E. Leiberman, Z. Zadik, Y. Giat, J. Levy, and A. Tal. Integrated plasma cortisol concentration in children with asthma receiving long-term inhaled corticosteroids. Pediat. Pulmonol. 12:84-89 (1992).
22. K. M. Tornatore, G. Logue, R. C. Venuto, and P. J. Davis. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J. Clin. Pharmacol. 37:304-311 (1997).
23. H. Möllmann, H. Derendorf, J. Barth, B. Meibohm, M. Wagner, M. Krieg, H. Weisser, J. Knöller, A. Möllmann, and G. Hochhaus. Pharmacokinetic/pharmacodynamic evaluation or the systemic effects of flunisolide after inhalation. J. Clin. Pharmacol. 37:893-903 (1997).
24. H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, R. Stöckmann, M. Krieg, H. Weisser, C. Falcoz, and H. Derendorf. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur. J. Clin. Pharmacol. 53:459-467 (1998).
25. B. A. Zaborny, P. Lukacsko, I. Barimov-Colligon, and J. A. Ziemniak. Inhaled cortico-steroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. J. Clin. Pharmacol. 32:463-469 (1992).
26. H. Derendorf, H. Möllmann, J. Barth, C. Möllmann, S. Tunn, and M. Krieg. Pharmacokinetics and oral bioavailability of hydrocortisone. J. Clin. Pharmacol. 31:473-476 (1991).
27. M. Gibaldi and D. Perrier. Pharmacokinetics. Marcel Dekker, New York, 1982.
28. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, and H. Derendorf. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone Pharm. Res. 12:1096-1100 (1995).
29. H. Möllmann, P. Rohdewald, J. Barth, M. Verho, and H. Derendorf. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm. Drug Dispos. 10:453-464 (1989).
30. A. Grahnen, S. A. Eckernäs, R. Brundin, and A. Ling-Andersson. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38:521-525 (1994).
31. A. Lönnebo, A. Grannen, B. Jansson, R. M. Brundin, A. Ling-Andersson, and S. A. Eckernäs. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur. J. Clin. Pharmacol. 49:459-463 (1996).
32. J. Corren, G. Rachelefsky, and G. Hochhaus. A five-way parallel randomized study to compare the safety profile of beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide in healthy male volunteers. Chest 110:83S (1996).
33. M. Boorsma, N. Andersson, P. Larsson, and A. Ullmann. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur. Respir. J. 9:1427-1432 (1996).
34. A. Grahnen, B. Jansson, R. M. Brundin, A. Ling-Andersson, A. Lönnebo, M. Johansson, and S. A. Eckernäs. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur. J. Clin. Pharmacol. 52:261-267 (1997).
35. E. Derom, J. Van Schoor, W. Vincken, M. Huybrechts, P. Remgard, M. Persson, and R. Pauwels. A comparison of the systemic activity of two doses of inhaled fluticasone propionate and budesonide in asthmatic patients. Eur. Resp. J. 9:162s (1996).
36. S. Pedersen and G. Fuglsang. Urine cortisol excretion in children treated with high doses of inhaled cortisteroids: a comparison of budesonide and beclomethasone. Eur. Resp. J. 1:433-435 (1988).
37. U. Tauber, K. Richter, and H. Matthes. Fluocortolone: Pharmacokinetics and effect on plasma cortisol level. Eur. J. Clin. Pharmacol. 30:433-438 (1986).
38. S. Edsbäcker, K. E. Andersson, and A. Ryrfeldt. Nasal bioavailability and systemic effects of glucocorticoid budesonide in man. Eur. J. Clin. Pharmacol. 29:477-481 (1985).
39. D. J. Clark, A. Grove, R. I. Cargill, and B. J. Lipworth. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266 (1996).
40. B. Volovitz, A. Kauschansky, M. Nussinovitch, L. Harel, and I. Varsano. Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. J. Allergy Clin. Immunol. 96:874-878 (1995).
41. Z. Zadik, L. De Lacerda, L. A. De Carmargo, B. P. Hamilton, C. J. Migeon, and A. A. Kowarski. A comparative study of urinary 17-hydroxycorticosteroids, urinary free cortisol, and the integrated concentration of plasma cortisol, J. Clin. Endocrinol. Metab. 51:1099-1101 (1980).
42. A. E. Mackie, C. Falcoz, J. McDowall, J. Moss, G. P. Ventresca, and A. Bye. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in healthy subjects. Br. J. Clin. Pharmacol 43:540P-541P (1997).
43. L. Thorsson, K. Dahlström, S. Edsbäcker, A. Källen, J. Paulson, and J.-E. Wiren. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 43:155-161 (1997).
44. G. Babadjanova, B. Allolio, M. Vollmer, M. Reincke, and H. M. Schulte. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. Eur. J. Clin. Pharmacol. 51:53-57 (1996).
45. J. J. Condemi, P. Chervinsky, M. F. Goldstein, L. B. Ford, W. E. Berger, G. H. Ayars, P. R. Rogenes, L. Edwards, and P. J. Pepsin. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered dose inhaler in patients with persistent asthma. J. Allergy Clin. Immunol. 100:467-474 (1997).
46. K. J. Wiessmann and M. Trautmann. Fluticasone propionate (500μg daily) and flunisolide (1000 μg daily) in the treatment of steroid-naive patients with moderate asthma. Eur. Resp. J. 7:383s (1994).
47. K. Bergmann. Controlled clinical comparative evaluation of fluticasone powder inhalation versus flunisolide dose aerosol in patients with mild to moderate asthma. Pneumologie 51:27-32 (1997).
48. A. K. Kamada, S. I. Szefler, R. J. Martin, H. A. Boushey, V. M. Chinchilli, J. M. Drazen, J. E. Fish, E. Israel, S. C. Lazarus, R. M. Lemanske, and A. C. R. Group. Issues in the use of inhaled glucocorticoids. Am. J. Respir. Crit. Care Med. 153:1739-1748 (1996).
49. G. Würthwein, S. Rehder, and P. Rohdewald. Lipophilicity and receptor affinity of glucocorticoids. Pharm. Zeit. Wiss. 137:161-167 (1992).
50. I. Vachier, S. Roux, P. Chanez, J. Loubatiere, B. Terouanne, J. C. Nicolas, and P. Godard. Glucocorticoids induced down-regulation of glucocorticoid receptor mRNA expression in asthma. Clin. Exp. Immunol. 103:311-315 (1996).
51. R. Schlaghecke, D. Beuscher, E. Kornely, and C. Specker. Effects of glucocorticoids in rheumatoid arthritis. Arthritis Rheumat. 37:1127-1131 (1994).
52. S. Goldberg, N. Algur, M. Levi, E. Brukheimer, H. J. Hirsch, D. Branski, and E. Kerem. Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Ann. Allergy Asthma Immunol. 76:234-238 (1996).
53. P. Chamberlin and W. Meyer. Management of pituitary adrenal suppression secondary to corticosteroid therapy. Pediatrics 67:245-251 (1981).
54. C. M. Zwaan, R. J. H. Odink, H. A. Delemarre-van de Waal, J. E. Dankert-Roelse, and J. A. Bokma. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet 340:1289-1290 (1992).
55. J. Wong and P. Black. Acute adrenal insufficiency associated with high-dose inhaled steroids, Br. Med. J. 304:1415 (1992).